Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 13%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp is experiencing robust growth, as evidenced by a significant 65% year-over-year increase in its core exome/genome revenue, alongside a consistent rise in average selling prices (ASPs) and testing volumes. The company's strategic shift towards exome and genome-based panels is also notable, projecting a mix shift to 43% of volumes by Q3 2025, supported by an increase in gross margins forecasted to 70%-71%. Furthermore, the positive outlook is corroborated by an upward revision of 2025 revenue guidance to between $425 million and $428 million, highlighting the company's strong positioning in the precision medicine sector.

Bears say

GeneDx Holdings faces a significant cash burn of approximately $2 million per quarter, primarily attributed to challenges associated with its Fabric initiative, which raises concerns about the company’s operational sustainability. Additionally, the high denial rate of 45% for reimbursements from third-party payers, despite being contracted with around 80% of health plans, indicates potential difficulties in achieving future commercial success. Furthermore, disruptions in data and workflow services, coupled with the necessity for a consistent supply of sequencers and materials, pose risks to GeneDx's financial condition and may hinder its growth prospects in the precision medicine sector.

WGS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 13% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Buy based on their latest research and market trends.

According to 8 analysts, WGS has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $138.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $138.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.